Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D. Tap, Andrew J. Wagner, Javier Martín‐Broto et al.|The Lancet|2019Cited by 472
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip Pravin Patel, Razelle Kurzrock, Megan Othus et al.|Clinical Cancer Research|2020Cited by 326
Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology GroupChristopher W. Ryan, E. David Crawford|Journal of Clinical Oncology|2007Cited by 152
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing ResultsMichael C. Heinrich, Laurence H. Baker, Cathryn Rankin et al.|JAMA Oncology|2017Cited by 126